Predicting adverse outcomes in primary Sjögren's syndrome: Identification of prognostic factors

Department of Autoimmune Diseases, School of Medicine, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain.
Rheumatology (Impact Factor: 4.48). 09/2007; 46(8):1359-62. DOI: 10.1093/rheumatology/kem079
Source: PubMed


To identify features present at diagnosis that were prospectively associated with adverse outcomes in a large cohort of patients with primary Sjögren's syndrome (SS).
Two hundred and sixty-six patients diagnosed with primary SS in our department between 1984 and 2002 were consecutively included and followed up. Outcomes measured were vasculitis, B-cell lymphoma and death. Cox regression analysis was used to evaluate the effect of variables at diagnosis on outcomes.
Twenty-five (9%) patients developed vasculitis. Multivariate analysis identified parotid scintigraphy grades III or IV (HR 3.55, P = 0.05) and C4 levels <0.11 g/l (HR 8.26, P < 0.001) as variables predicting the development of vasculitis. Nine (3%) patients developed B-cell lymphoma. Multivariate analysis identified C3 levels <0.82 g/l (HR 7.54, P = 0.016) as a predictive factor of lymphoma development. Twenty-five (9%) patients died during follow-up. Systemic involvement (HR 4.51, P = 0.022), vasculitis (HR 4.58, P = 0.042), C4 levels <0.11 g/l (HR 5.47, P = 0.027) and cryoglobulins (HR 4.58, P = 0.013) were independently associated with death. The presence of at least two of the above-mentioned predictive factors (parotid scintigraphy, vasculitis, hypocomplementaemia and cryoglobulinaemia) was associated with a lower survival in comparison with patients with no factor (log rank and Breslow tests <0.001).
The main prognostic factors for an adverse outcome identified in our cohort of patients with primary SS were vasculitis, severe involvement in parotid scintigraphy, hypocomplementaemia and/or cryoglobulins at diagnosis. Patients with at least two of these factors need a closer follow-up.

Full-text preview

Available from:
  • Source
    • "In other autoimmune diseases, such as systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS), the serum level of complement decrease at relapse because of consumption. And this can help to predict the prognosis of these diseases [14-17]. C-reactive protein (CRP) is a component of the innate immune system, which reflects systemic low-grade inflammatory activity [18]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuromyelitis optica (NMO) shows various brain magnetic resonance imaging (MRI) abnormalities with recurrent central nervous system (CNS) attacks, although predominantly affecting the spinal cord and optic nerve. However, NMO with extensive involvement of the brain has infrequently been studied. We investigated the clinical, radiographic features and immunomodulating changes of NMO patients with extensive brain lesions (EBLs) in China. NMO patients (including 16 NMO patients with EBLs and 53 NMO patients without EBLs) hospitalized during January 2006 and February 2010 were recruited and analyzed retrospectively. Data of clinical characteristics, magnetic resonance imaging (MRI) features, laboratory abnormalities, treatment details and outcomes were analyzed. All the patients received the follow-up visits for two years. EBLs in NMO were classified into four categories according to their respective MRI characteristics: 1) Tumefactive-like lesions (n=4, 25%); 2) Acute disseminated encephalomyelitis (ADEM)-like lesions (n=6, 37.5%); 3) Multiple sclerosis (MS)-like lesions (n=5, 31.25%); 4) Posterior reversible encephalopathy syndrome (PRES)-like lesions (n=1, 6.25%). NMO patients with EBLs had higher rates of encephalopathy symptoms (37.5% vs.5.6%, p = 0.004), homonymous hemianopia (18.8% vs. 0%, p = 0.011) and AQP4 seropositivity (100% vs.69.8%, p = 0.008) than NMO patients without EBLs (NEBLs). Immunomodulating changes (including the levels of C3, C4, ESR and CRP) were significantly higher in patients with EBLs than those without EBLs. The relapse times in EBLs during the follow-up period were more frequent than those happened in NEBLs (1.88 +/- 0.30 vs. 1.23 +/- 0.14, p = 0.04). The EDSS scores in EBLs patients were also much higher than those in NEBLs throughout all the whole visits of follow-up. The presence of EBLs in NMO may indicate a higher diseases activity and portend a worse prognosis. CRP is a useful marker in monitoring diseases activity. Systemic inflammation may be crucial to the formation of EBLs in NMO.
    BMC Neurology 07/2013; 13(1):72. DOI:10.1186/1471-2377-13-72 · 2.04 Impact Factor
  • Source
    • "Sjogren's syndrome is a systemic autoimmune exocrinopathy involving the salivary glands, but it can also involve almost every other part of the GI tract. Systemic vasculitic manifestations of Sjogren's syndrome have been reported in approximately 10% of patients [23]. Only one study of multiple colonic ulcers due to vasculitis associated with Sjogren's syndrome has been reported in the Japanese literature [24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The patient was a 36-year-old woman with sarcoidosis and Sjogren's syndrome, and had been prescribed slow-release diclofenac sodium and prednisolone for the treatment of pain associated with uveitis and erythema nodosum. She was admitted to our emergency center with abdominal pain and distention. A chest X-ray showed free air under the diaphragm on both sides, and an emergency laparotomy was performed for suspected panperitonitis associated with intestinal perforation. Laparotomy revealed several perforations on the antimesenteric aspect of the transverse colon. The resected specimen showed 11 punched-out ulcerations, many of which were up to 10 mm in diameter. The microscopic findings were non-specific, with leukocytic infiltration around the perforations. She showed good postoperative recovery, as evaluated on day 42. The present case highlights the need for exercising caution while prescribing slow-release nonsteroidal anti-inflammatory drugs with corticosteroids to patients with autoimmune diseases, as such treatment may exacerbate intestinal epithelial abnormalities.
    07/2011; 2011. DOI:10.1155/2011/824639
  • [Show abstract] [Hide abstract]
    ABSTRACT: Das nach den AECG-Kriterien diagnostizierte primäre Sjögren-Syndrom (pSS) ist mit einer Prävalenz von rund 0,2% in der erwachsenen Normalbevölkerung und einer Jahresinzidenz von 4/100.000 Gesamtbevölkerung deutlich seltener als bisher angenommen. Auch der wiederkehrend berichtete Anteil von einem Mann auf 9Frauen dürfte eher bei etwa 1:20 liegen. An pSS erkrankte Männer haben seltener immunologische, histopathologische oder sialographische Befunde und Organbeteiligungen. Das Erkrankungsalter liegt in jüngeren Untersuchungen mit rund 45Jahren um rund 10Jahre niedriger als in solchen des letzten Jahrzehnts. Im jüngeren Alter erkrankte Patienten sind häufiger Rheumafaktor- und/oder Anti-Ro/SS-A-positiv und leiden häufiger an Hypokomplementämie oder Lymphadenopathien. Mit der Einführung der spezifischeren AECG-Kriterien finden sich weniger Männer, mehr jüngere und mehr schwer erkrankte Patienten in pSS-Kohorten. Etwa 5–10% der pSS-Patienten spezialisierter Zentren leiden an schwerwiegenden extraglandulären Manifestationen. Diese zeigen sich zumeist früh im Krankheitsverlauf und gehen z.T. mit erhöhter Mortalität einher. Betroffene ohne früh auftretende Organbeteiligungen können mehrheitlich mit einem leichten bis mäßig schweren Verlauf rechnen. In Deutschland wird nur rund ein Zehntel der Sjögren-Kranken rheumatologisch betreut. Zusammen mit den nach AECG-Kriterien nicht berücksichtigten Anti-Ro/La-negativen Sjögren-Kranken und den Patienten mit sekundärem Sjögren-Syndrom dürften mindestens 0,4% der erwachsenen Bevölkerung unter stark beeinträchtigender immunpathologischer Sicca-Symptomatik leiden. According to the classification criteria of the American-European Consensus Group (AECG), the prevalence of primary Sjögren’s syndrome (pSS) of about 0.2% in the adult population and a yearly incidence of 4/100.000 in the general population are far lower than previously assumed. Moreover, the repeatedly reported male/female ratio of 1:9 seems to lie more in the range of 1:20. Male pSS patients show fewer immunological, histopathological or sialographic findings and organ involvement. Information on age at disease onset has also changed over the last decade. Recent studies indicate an onset age of approximately 45 years as compared to 56 in earlier studies of the last decade. Patients with an early disease onset are more frequently positive for rheumatoid factor (RF) and/or anti-Ro/SS-A. These patients also seem to have a higher risk of developing hypocomplementemia or lymphadenopathy. As compared to earlier cohorts, the introduction of the rather specific AECG criteria will probably result in the participation of fewer men, younger patients in general and of more seriously ill patients in future cohorts. The change in the spectrum of pSS patients obviously reflects the altered classification criteria since the AECG criteria require anti-Ro/La positivity and therefore exclude a high number of patients with other immunological markers who also show severe sicca symptoms and organ involvements. About 5%–10% of pSS patients in rheumatological care suffer from severe extraglandular manifestations, which generally occur soon after disease onset. In particular, palpable purpura, hypocomplementemia, cryoglobulinemia and lymphoma are associated with increased mortality. In Germany, approximately one tenth of Sjögren syndrome patients receive specialized rheumatological care. There is still insufficient knowledge about the vast majority of pSS patients who are not treated by rheumatologists. These patients, as well as all those who, according to the AECG criteria, are not classified as having pSS either due to anti-Ro/La negativity or having secondary Sjögren’s syndrome, probably add up to at least 0.4% of the adult population which, at present, suffers from considerable immunopathologic sicca symptoms.
    Zeitschrift für Rheumatologie 02/2009; 69(1):41-49. DOI:10.1007/s00393-009-0518-3 · 0.61 Impact Factor
Show more